MedTrace Logo

A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors

NCT06618651 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2025-11-17

No results posted yet for this study

Summary

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

SHR-3821 injection

SHR-3821 injection

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2026-01-01
Completion
2027-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618651 on ClinicalTrials.gov